CTD Announces Support and Participation at Annual Family Conference of National Niemann-Pick Disease Foundation

ALACHUA, Fla.–(BUSINESS WIRE)–CTD Holdings, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced the Company’s sponsorship and participation of the annual gathering of families supported by that National Niemann-Pick Disease Foundation (NNPDF). The NNPDF is a non-profit organization dedicated to supporting and empowering patients and families affected by Niemann-Pick Disease through education, collaboration and research. This is CTD’s fourth year of supporting the conference with an unrestricted grant and in presenting on the company’s clinical program in Niemann-Pick Disease Type C (NPC).

“As we work to develop Trappsol^® Cyclo™ as a treatment for NPC, it is critical that we listen to families and share information on our drug development progress.” Said CTD Chairman and CEO N. Scott Fine, “The NNPDF annual gathering represents an important venue for us to learn and share.”

“NNPDF is grateful to all of our sponsors, including CTD.” Added NNPDF Executive Director Joslyn Crowe, “Without sponsor support, the annual gatherings of families who are struggling with NPC would not be possible. For the community, such gatherings are critical as families cope, share best practices, and find sources of support.”

The conference will take place at the Hilton Minneapolis, MN between August 15-18, 2019.

CTD will be represented by:

• Mr. N. Scott Fine, Chairman and CEO,
• Ms. Sharon Hrynkow, Ph.D., Chief Scientific Officer and Senior Vice President for Medical Affairs, and
• Ms. Shannon Reedy, Family Liaison.
• Dr. Caroline Hastings, M.D., Pediatric Hematologist/Oncologist and senior clinician-scientist and educator at the UCSF Benioff Children’s Hospital, Oakland CA, will join the team. Dr. Hastings is the Principal Investigator for CTD’s U.S.-based trial for Trappsol^® Cyclo™.

CTD will lead or present at the following sessions:

Thursday, August 15, morning session: Family Advisory Working Group, an opportunity for CTD to connect directly with NPC patients and caregivers to gain insight into the patient and family experience.

Friday, August 16, afternoon session on FDA Approved, Recruiting and Active NPC Clinical Trials. Dr. Hastings will present initial findings from the US clinical trial and from a companion Phase I/II trial in Europe and Israel. The presentation will be followed by a panel Q and A session with Dr. Hrynkow and Dr. Hastings.

About CTD Holdings:

CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol^® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease, on a compassionate use basis as well as in three ongoing formal clinical trials (Clinical Trials.gov NCT02939547, NCT02912793 and NCT03893071). Additional indications for the active ingredient in Trappsol^® Cyclo™ are in development. For additional information, visit the company’s website: www.ctd-holdings.com

Safe Harbor Statement:

This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contacts

Investor/Media Contact:

Sitrick and Company

Wendy Tanaka

(415) 369-8447

[email protected]